Exhibit 10.8(f)


 Exhibit 10.8(f) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 Contract Amendment No. 5 

to the 
 Development and Supply
Agreement as of May 29, 2008 
 by and between 

ViewRay Incorporated, 
 with
its registered seat in Oakwood Village, OH, USA 
 - hereinafter referred to as “Viewray” - 

and 
 Siemens AG 

Healthcare Sector 
 -
hereinafter referred to as “Siemens” - 
 - VIEWRAY and Siemens hereinafter referred to individually 

as “Party” or collectively as “Parties” - 

Preamble 
 The Parties have signed a
Development and Supply Agreement on May 29, 2008, as amended (the “2008 Agreement”) with the intention to collaborate in the development of combining MR imaging and gamma radiotherapy. In this Contract Amendment No. 5, the
Parties agree to make certain amendments to the 2008 Agreement as described below. 
 Agreement 

Article 1. Amendment to Article 1.1 of Annex 2 in Appendix 2 

The first three sentences of Article 1.1 of Annex 2 in Appendix 2 of the 2008 Agreement (the Supply Agreement) are hereby amended to read in
full as follows: 
 “1.1 SELLER will provide BUYER with a list of COMPONENTS, with their part number and part description, in a form similar to the
following list. 
 [***] 
 The components in
the list may be updated from time to time with respect to model numbers, SELLER shall notify the BUYER of any changes. BUYER is also allowed to request of SELLER to add other items onto the list, BUYER’S consent will not be unreasonably
withheld. 
 The prices for COMPONENTS shall be EXW (Incoterms 2000) including packaging. The valid prices for COMPONENTS shall be communicated separately
by the SELLER to the BUYER on or before the Effective Date of this Contract Amendment No. 5. The SELLER shall inform the BUYER giving at least three (3) months notice about price changes with new pricing becoming effective only after such
notice period.” 






 The Table at the end of Article 1.1 is deleted and replaced with a list of COMPONENTS, which will be
provided on or before the Effective Date of this Contract Amendment No. 5. 
 Article 2. Amendment to Article 1.2 of Annex 2 in
Appendix 2 
 Article 1.2 of Annex 2 in Appendix 2 of the 2008 Agreement (the Supply Agreement) is hereby amended to read in full as
follows: 
 “1.2 The price shall be net, fixed in US $. Any fiscal charges, taxes, etc., that arise shall be listed separately.” 

Article 3. Duration: 
 This Contract Amendment No. 5
shall take effect on the date it is signed by both Parties. 
 Article 4. Miscellaneous: 

4.1 Except to the extent expressly amended by this Contract Amendment No. 5, all of the clauses and conditions of the 2008 Agreement shall remain
unaffected. The term “Agreement”, as used in the 2008 Agreement, shall henceforth be deemed to be a reference to the 2008 Agreement as amended by this Contract Amendment No. 5. 

4.2 This Contract Amendment No. 5 may be executed in counterparts, each of which will be deemed an original with all such counterparts together
constituting one instrument. Capitalized terms used in this Contract Amendment No. 5 and not defined herein are used with the meanings ascribed to them in the 2008 Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 








					
	ViewRay Incorporated	 		 	
			
	Place, Date:	 		 	
			
	Oakwood, OH, USA, 30 May 2012	 		 	  

		 		 	
	Name:     Greg Ayers, M.D. Ph.D.	 		 	
	Title:     Chief Executive Officer	 		 	

  

					
	 Siemens AG.,
 Healthcare
Sector
	 		 	
			
	Place, Date:	 		 	
			
	Erlangen, 04.05.12	 		 	Erlangen, 9.5.12
			
	/s/ I.V. Zindel	 		 	/s/ Holger Liebel
	Name:     Dr. Christoph Zindel	 		 	Name:    Holger Liebel
	(Print)	 		 	(Print)
	Title:     VP Marketing MR	 		 	Title:     CFO Magnetic Resonance
		 		 	
		 		 	


  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 







 Valid from 1.01.2011 to 1.01.2013 

[***] 

  
 [***] Two pages this document have been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.